Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases and orphan indications. Its lead product candidate is Narsoplimab (OMS721/MASP-2), which targets hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) and is also in a Phase II trial for COVID-19 and acute respiratory distress syndrome. The company also has OMS1029, which completed Phase I trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders, and OMS527, in Phase I for addictions, compulsive disorders, movement disorders, and cocaine use disorder. Preclinical programs include MASP-2 inhibitors, MASP-3 small-molecule inhibitors for alternative pathway disorders, OncotoX-AML for acute myeloid leukemia, and Targeted Complement Activating Therapy for multidrug-resistant organisms.

Omeros Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol OMER. The company trades in U.S. dollars (USD), which is the currency of its home country, the United States. As a Nasdaq-listed company, OMER shares are accessible to investors through major brokerage platforms, and its financial reporting is conducted in USD.

Omeros Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing therapeutics for immunologic diseases and orphan indications. Biotechnology companies like Omeros use biological processes to create drugs, often targeting specific molecular pathways, and Omeros specializes in complement pathway inhibitors and other protein therapeutics.

Omeros Corporation is headquartered in Seattle, Washington, United States. The company primarily serves the U.S. market, as indicated by its region designation 'us'. While its clinical trials and regulatory activities are focused in the United States, its therapeutic candidates target global health issues such as thrombotic microangiopathy, COVID-19, and acute myeloid leukemia. The company's operations are based in the U.S., and it was incorporated in 1994.

Omeros Corporation is a clinical-stage biopharmaceutical company, meaning it has not yet generated revenue from product sales as its candidates are still in development. Its business model involves discovering and developing small-molecule and protein therapeutics for immunologic diseases and orphan indications. The company advances its pipeline through preclinical and clinical trials, with the goal of obtaining regulatory approval and eventually commercializing its drugs. Key programs include Narsoplimab for TA-TMA and COVID-19, OMS1029 for MASP-2 disorders, and OMS527 for addictions. Omeros also has preclinical assets like MASP-3 inhibitors and OncotoX-AML. Revenue, if any, would come from future product sales, licensing agreements, or partnerships, but currently the company is pre-revenue and focuses on R&D.